A melanoma model demonstrated that Lactobacillus kefiranofaciens ZW18 (1 × 109 cfu/day) had the best anti-melanoma effect when administered along with PD1-inhibitor anti-cancer therapy, enhancing the body’s immune response by promoting the infiltration of CD8+ T cells [53]. This evidence concerns the gene CD8A and melanoma.